Development of radiolabeled 111In-albumin liposomes for long-term imaging of tumors Authors: Mohammad Ahrari, Zahra Saberi, Azam Abbasi, Jafar Rahnama Yazdi, Mahmoud Reza Jaafari, Kayvan Sadri Published: 2026 ABSTRACT AbstractBackgroundThe current study aims to develop a clinically applicable radiopharmaceutical agent for long-term imaging in the diagnosis and management of oncologic patients in the field of nuclear medicine. Liposomes, as pharmaceutical nanocarriers, have been extensively studied in pharmaceutical industry and depending on their structural characteristics could be formulated for accumulation in various pathological sites in the body. PEGylated liposomes have smaller volume of distribution and decreased clearance, consequently, due to their more prolonged presence in the bloodstream and their stability during this time, could be used for tumor imaging.Study design and methods In this work, liposomal formulations encapsulating albumin were synthesized by thin-film hydration technique, then extruded and after homogenization, their characteristics including size, zeta potential and encapsulation efficiency were measured. Then, these liposomes were labeled by 111In-oxine and their stability in serum medium was assessed and the rate of their biodistribution in C26-colon carcinoma tumor-bearing mice was evaluated by two approaches, quantitatively radioactivity measurement and qualitatively gamma scintigraphy imaging.ResultsThe result of our study displayed that 111In -radiolabeled liposomes having a size of about 130 nanometers, were capable of accumulating in tumor sites based on enhanced penetration and retention (EPR) phenomenon. These liposomes also have high stability for maintaining encapsulated albumin for a long time up to 96 h and even may be stable for longer time period. In the study of biodistribution of our formulation in tumor-bearing mice, they accumulated more in the kidney, liver, spleen and tumor sites, so that even after clearance of formulation in the bloodstream, they existed in significantly higher levels in the mentioned organs and likewise tumor sites up to 96 h. In gamma scintigraphy, organs with high activity resulted from accumulation, were visible in the form of hot spots demonstrating formulation stability in the tumor sites from time of administration to 96 h.ConclusionsOur in vitro and in vivo studies demonstrated that this PEGylated radiolabeled liposomal formulation have considerable stability and efficiency for long-term tumor imaging which merit further studies for its transformation into clinical application.Keywords: 111In-albumin, Nanoliposome, Biodistribution, Tumor imaging Introduction Gamma ray imaging or scintigraphy is a valuable tool in the optimal design of the liposomal formulation of radiopharmaceutical agents, and allows non-invasive tracking of the distribution of radiolabeled liposomes in the body by gamma ray (Goins and Phillips 2001). While radiological imaging techniques such as MRI and CT give anatomical information, centigram images display the distribution of radiopharmaceuticals in the body milieu and determine variations in physiological processes. It is well known that the diagnosis of various tissue damages, tumor cells or infectious foci can be determined by traditional Gamma ray imaging before the appearance of anatomical abnormalities. Furthermore, the early diagnosis of suspected area of above pathologic lesions is of great importance in terms of clinical application (Boerman et al. 2000). Liposomes have been labeled with gamma irradiating radiopharmaceuticals such as 67Ga, 111In and 99mTc for the purpose of tumor imaging. Radiolabeled liposomes have been exploited for imaging of tumor, infectious foci, and blood pool, and there are large amount of preclinical evidence showing these liposomes can image tumors sites and other inflammatory lesions with considerable specificity and sensitivity. Moreover, according to the biodistribution profiles obtained in the studies on rabbits, it has been determined that PEGylated liposomes can maintain their shielding properties more than other conventional types of liposomes. Immediately removal of non-PEGylated liposome by MPS phagocytizing cells in the liver and spleen greatly limited their utilization inside the human body. Subsequent progress in the field of long-circulating liposomes (LCLS) has created nanoliposomes that are less likely to be taken up by the cells of the mononuclear phagocyte system (MPS) of the body. The development of these LCLs by enhancing their circulating half-life has increased our ability to detect pathological processes by in vivo scintigraphy procedures (Boerman et al. 2000; Awasthi et al. 2003; Low et al. 2023). The researches of several decades provide a depth understanding of the effects of liposomal characteristics such as size, type and concentration of lipids, surface charge and hydrophilicity, on their pharmacokinetic after intravenous administration. In particular, modifying the surface characteristics of liposomes and the use of nanoliposomes with approximately 100 nm size, containing more cholesterol and phospholipids with saturated chains enhances the circulation time of liposomes in the blood and reduces their removal by the reticuloendothelial system (Chow et al. 2009; Man et al. 2019). Today, 99mTc radiopharmaceutical is used in nuclear medicine departments, which has a short half-life. For evaluating some diseases, especially tumors, we need a radiopharmaceutical agent with long shelf life. 111In is a radionuclide which could be obtained as 111In-oxine with a specific activity of 15 mCi/ml from Atomic Energy Organizations. It does not have beta irradiation and emits two gamma photons with energy of 173 Kev and 247 Kev, which are used in clinical imaging. 111In have been used for cell radiolabeling by binding to cellular proteins. Furthermore, the binding of 111In with proteins such as albumin is 1012 folds stronger than its binding with oxine (oxyquinoline) (Awasthi et al. 1997; Dillehay et al. 2006; Phillips et al. 2009; Drozdovitch et al. 2015; Lamichhane et al. 2017; De Silva et al. 2019). In this study, we used this phenomenon and prepared albumin-loaded liposomes. By analogy, we could consider liposomes as to cells and the albumin as to cytoplasmic proteins. Subsequently albumin-loaded liposomes were radiolabeled with 111In-oxine. Unlike HMPAO (hexamethylpropyleneamine oxime), which is trapped inside the liposome, oxine after separation from 111In, releases from liposomes through the lipid bilayer and transfers into the aqueous phase. This process results in the entrapment of 111In-albumin complex inside the liposome while excluding oxine. This approach has made efficient method for production of radiolabeled liposomes to be utilized in tumor imaging. In imaging with radiolabeled liposomes, the metastatic area inside the liver and spleen are identified as cold spots (Jaggi et al. 1991). For this purpose, almost all traditional liposomal formulations could be used. The development of liposomal radiopharmaceuticals to determine the location of tumors was perceived since it was shown that well developed liposomal formulations could accumulate at the tumor site. The development of liposomes with longer half-life in the circulation has increased the expectation of using these liposomal radiopharmaceuticals in tumor imaging. The capability of liposomal formulations labeled with 99mTC, 67Ga and 111In in identifying tumors has been proven in numerous studies (Presant et al. 1988; Ogihara-Umeda et al. 1992, 1996). Several studies have shown that liposomes with longer half-life and higher stability in the circulation well demonstrated improved uptake in tumor cells (Boerman et al. 1995; Ishida et al. 1999; Phillips 1999; Dams et al. 2000; Lee et al. 2005). In regarding these considerations, the present work aims to combine these approaches in the development of a radiopharmaceutical agent for long-term tumor imaging. Methods Materials Human Albumin 20% solution was purchased from Biotest, Germany. The phospholipids, hydrogenated soya phosphatidylcholine (HSPC), methoxypolyethelene glycol (MW 2000)-distearylphosphatidylethanolamine (mPEG2000-DSPE), were obtained from Lipoid (Ludwigshafen, Germany). Cholesterol and Sephadex G-50 were purchased from Sigma–Aldrich (St. Louis, MO). 111In-oxine with a specific activity of 15 mCi/ml was purchased from Parse Isotope Co, Iran. All other used chemicals were of analytical grade. Preparation of albumin-loaded liposomes Liposomes were prepared by thin film hydration method plus extrusion (Nikpoor et al. 2015). The total lipid concentration of all the liposomal formulations was adjusted 48mM. In brief, HSPC, cholesterol and mPEG2000-DSPE, that all of them were dissolved in chloroform, were mixed at the molar ratios presented in Table 1. Then, evaporation of organic solvent was performed by a rotary evaporator in three hours, followed by three hours’ freeze drying for optimal dryness of thin film layer. The dried lipid film was hydrated with albumin solution by rotating in a water bath at 60 °C and gentle mixing on a vortex mixer until thin film dissolved thoroughly. Afterward, liposomes in solution were downsized by extrusion through polycarbonate membrane filters 400 nm, 200 nm and 100 nm (11 times each) at 60 °C to reach the optimized size. The resulting liposomal products were purified by dialysis. In the dialysis method, free albumin molecules which weren’t entrapped in liposomes, removed from liposomal formulations in 300 KDa molecular weight cut-off dialysis membrane (Spectrum) by dialyzing against HEPES 10 mM and sucrose 7.5% buffer (pH ~ 7.4). The final liposomal solutions were stored at 4 °C until later use. Blank liposomes (without albumin) were prepared following the same procedures mentioned before, with hydration solution excluding albumin. Table 1Particle size, PDI and zeta potential of liposomes encapsulating albumin. (n = 3)Albumin-loaded liposomal formulationMolar ratio (%)Zeta average size (nm) ± SDPolydispersity± SDZeta potential (mV)Entrapment efficiency%HSPC/CHOl/mPEG2000-DSPE (48 mM)55/40/5130.8 ± 1.20.175 ± 0.014− 15.47 ± 3.1946.5 ± 3 Particle size, PDI and zeta potential of liposomes encapsulating albumin. (n = 3) Characterization of albumin-loaded liposomes Particle size, PDI and zeta potential measurement Particles size, PDI (polydispersity index) and zeta potential of liposomes were measured by the dynamic light scattering(DLS) technique in a Zetasizer Nano ZS instrument (Malvern Instruments, CO., UK). The measurements were performed at 25 °C after the dilution of formulation with HEPES 10 mM and sucrose 7.5% buffer (pH ~ 7.4). Zeta potential of liposomes was measured using electrophoretic light scattering by the same instrument. The results of particle size and zeta potential were expressed as mean ± S.D. (n = 3). Encapsulation efficiency measurement Encapsulation efficiency of albumin in liposomes was determined by separating free albumin from albumin-loaded liposomes using ultrafiltration method. Predialyzed samples were placed in the upper chamber of an Ultra-4 centrifugal filter unites with a molecular weight cut-off of 300 KDa (Amicon® Ultra-0.5, MWCO 300,000 Da; Millipore, Boston, USA) and centrifuged at 4000 g for 20 min at 8 °C. The free albumin was separated from liposomes and collected in the bottom of the tube. The concentration of albumin in filtrate was determined using BCA protein assay and encapsulation efficiency was calculated (Nikpoor et al. 2017). In BCA protein assay method for encapsulated albumin in liposomes, the interfering substances were removed via sample pretreatment by sodium deoxycolate and trichloroacetic acid. Encapsulation efficiency of albumin in liposomal formulations was determined by this equation: % Encapsulation: ([albumin content after purification (by dialysis)] ÷ [albumin content before purification]) × 100. Phosphate assay of liposomal formulation In order to determine phosphate content of albumin-loaded liposomes and its alteration in formulation process, Bartlett phosphate assay protocol for the liposomal formulations was performed (Shmeeda et al. 2003). The test was performed by this procedure and then concentration of phospholipids was calculated using standards. Morphology of albumin-loaded liposomes by transmission electron microscopy and atomic force microscopy The morphology of PEGylated albumin-loaded liposomes was determined using atomic force microscopy (AFM). This method of analysis determines surface structure of particles such as liposomes and provides three dimensional images. For AFM analysis, the formulation was diluted with dialyzed buffer (diluted 1:500) and about 30 µL of each sample were placed on a mika surface. After drying in room temperature, samples were analyzed by AFM microscope (NanoWizard®II, JPK model, Germany). By coming over cantilever tip on samples, imaging in 2, 5 and 10 μm scales was performed; therefore 2- dimensional and 3-dimensional images of liposomes were obtained. Radiolabeling of albumin- loaded liposomes Measurement of the radioactivity of 111In-oxine First, radioactivity of 111In-oxine complex was assessed. Briefly, by mixing 111In-oxine with chloroform and normal saline and then incubating them in room temperature two phases were formed. Radioactivity of chloroform and normal saline were measured. Free 111In enters saline phase due to its hydrophilicity and 111In-oxine enters chloroform phase due to its lipophilicity. Radiolabeling of albumin- loaded liposomes with 111In-oxine Albumin- loaded liposomes was labeled with 111In-oxine based on higher affinity of 111In to albumin that was a novel labeling approach. In brief, 1 mL of albumin-loaded liposomes mixed with 5 millicurie activity of 111In-oxine and then incubated in 55 °C for 20 min in a rotatory state. To separate labeled albumin-loaded liposomes with 111In from free 111In-oxine, sephadex G-25 size exclusion column chromatography was used. Phosphate buffered saline (PBS) was used for washing. The purified labeled albumin-loaded liposomes with 111In that are now called 111In-albumin liposomes, were collected in initial tubes and free 111In-oxine was separated in terminal tubes. Radioactivity of each tube was measured by the dose calibrator instrument. Sterilization of liposomal formulations For intravenous injection, the product must be sterile. Radiolabeled liposomal formulations were sterilized by disposable micro porous syringe filter with pore size of 220 nm under laminar flow hood and then collected in sterile tubes. Stability study of radiolabeled liposomal formulation in serum Stability of these liposomes was measured in serum medium by thin layer chromatography (TLC) method. Briefly, in the lower portion of silica gel strip, 50 µl of radioactive liposomes are loaded and then placed in serum medium. At 0.5-, 1-, 4- and 24-hour, silica gel strip was cut from its lower third portion and radioactivities of lower third and upper two third were measured. Released 111In from liposomal formulations in the incubation period moved along silica gel strip and reached to the upper portion. Therefore, upper portion of silica gel contains released 111In and the lower portion contains 111In-albumin encapsulated in liposomal formulations. In vivo studies Mice, used in this work, were BALB-c with 6 to 8 weeks age and 18 to 20 g, purchased from Pasteur institute of Iran (Tehran, Iran). Animal, were kept in the animal house of pharmaceutical research center, Buo Ali research institute, Mashhad University of Medical Sciences and had free access to water and animal food under appropriate environmental conditions. All animal experiments were conducted in accordance with the approval of Institutional Ethical Committee of Mashhad University of Medical Sciences. Induction of Balb-c mice model of C26 colon carcinoma C26 colon carcinoma cell line was used for induction of tumor in mice. This cell line was cultured in RPMI-1640 medium supplemented with 10% FBS and incubated in 37 °C incubator with 5% CO2. The mice were anesthetized by intraperitoneal injection of 200µL xylazine/ketamine (5:15) and then subjected to the administration of 3 105 × C-26 cells (in 60 µL volume) subcutaneously at their flanks. After one week, tumors were generated with the size of about 5 millimeters in each dimension at the flank of the mice. Intravenous injection of radiolabeled formulation to Balb-c mice For this step of our work, 15 mice were used, which were in 5 groups of 3. Mice in groups 1, 2, and 3 were administrated with 200µL (equal to 80 µCi) and groups 4 and 5 with 350µL (equal to 80 µCi) radiolabeled liposome intravenously by syringe. In other words, all mice received 80 µCi of the formulation. Their radioactivities were measured by the dose calibrator instrument. Also, after injecting into the mice and emptying the syringes, the amount of activity remaining in them was measured by dose calibrator and the quantity of radioactivity of each formulation injected into each mouse was calculated. Biodistribution of radiolabeled liposomes in Balb-c mice After administration of liposomal formulations, group 1 mice were sacrificed after 4 h, group 2 after 24 h, group 3 after 48 h, group 4 after 72 h, group 5 after 96 h, and their other organs (blood, heart, lungs, Liver, spleen, stomach, intestine, kidney, muscle tumor, tail and bone) were removed and placed into gamma tubes. The organs were washed with phosphate buffered saline, and weighted and the radioactivity of each organ was determined by a gamma counter (Delshid DL-100). The percentage of radioactivity per organ was measured as the mean injected dose per gram of organ (ID/g %) (Nikpoor et al. 2015). Gamma scintigraphy of Balb-c mice The biodistribution of liposomal formulations was furthermore investigated by planar photography method. Gamma cameras having the ability to receive gamma rays are used for this purpose. For this step of our experiment, 200 µCi of the formulation equivalent to 4.7 MBq of radiolabeled albumin loaded liposomes were injected intravenously through the mice tail vein. At 4, 24, 48, 96 h after administration, the mice were anesthetized by ketamine/xylazine and then planar photography of biodistribution of liposomes were prepared by a Siemens Dual head Gamma Camera device with a matrix of 300,000 and resolution of 256 × 256 pixel. The characteristics of imaging instrument were: Series: Static, Camera present: In111-NMG, Matrix Size: 64 × 64, Zoom: 2.29, Detectors: Both detectors, Ant: 5 min, Post: 5 min, Orientation: Head Out/Supine. Statistical analysis Data were presented as mean ± standard deviation (S.D.). The outcomes were analyzed by one-way analysis of variance (ANOVA) statistical test using GraphPad InStat version 3.05 for windows (GraphPad Software, USA). A statistical difference was considered when p value was less than 0.05. Results Formulation and characterization of albumin-loaded liposomes Particle size, PDI, zeta potential and encapsulation efficiency measurements Liposomal formulation (Table 1) containing albumin could be prepared reproducibly by thin film hydration method plus extrusion. Particle size, zeta potential and encapsulation efficiency of albumin-loaded liposomes were displayed in Table 1. Mean sizes of liposomes were about 130 nm by extrusion through polycarbonate membrane filter and encapsulation efficiency of liposomes for albumin ranged from 43% to 50%. PDIs of formulations were less than 0.2, indicative of almost homogenous distribution of liposomal sizes. Furthermore, phosphate concentration of the formulation was measured to be about 90 mM that was higher than expected based on formulation design, representing evaporation duration formulation preparation. Morphology of albumin-loaded liposomes by transmission electron microscopy and atomic force microscopy Figure 1 shows morphology of our albumin-loaded PEGylated liposomal formulation by both TEM and AFM microscopies. TEM microscopy depicts the structure and morphology of liposomes and AFM demonstrates their surface topology. As demonstrated by TEM and AFM microscopy, albumin-loaded liposomes had almost spherical shapes that were in expected correlation with the sizes obtained from DLS analysis. Morphology of albumin-loaded PEGylated liposomes by A Transmission Electron Microscopy and B Atomic Force Microscopy Radiolabeling of albumin- loaded liposomes Measurement of the radioactivity of 111In-oxine for quality control As displayed in Table 2, the percentage of 111In-oxine radioactivity was 20% that indicates its quality control for the study. Table 2Quality Control of 111In-oxine used in this experimentPhase typeRadioactivity (µCi)111In-oxine radioactivity percentNormal saline640(160 / (640 + 160)) *100%= 20%Chloroform160 Quality Control of 111In-oxine used in this experiment Radiolabeling and purification of albumin- loaded liposomes with 111In-oxine Figure 2 shows radiolabeling of albumin-loaded liposomes with 111In-oxine and purification of them from free 111In-oxine using Sephadex G-25. The first peak indicates the radiolabeled liposomes that used in our study and second peak is pertinent to free 111In-oxine that is excluded. Graphic representation of 111In radiolabeled albumin-loaded liposomes in peak 1 vs. free 111In in peak 2 Stability study of radiolabeled liposomal formulation in serum Stability of our formulation in serum medium was evaluated up to 24 h. Percentage of released 111In from liposomes indicating release percentage is presented in Fig. 3. At 0.5, 1, 4 and 24 h, remained radioactivity of our formulation is measured. Percentage of remaining radioactivity in albumin-111In-loaded liposomes in serum medium. n = 3 Biodistribution study of radiolabeled liposomes in tumor bearing mice by measurement of ID/g% The biodistribution of our albumin-loaded PEGylated liposomal formulation was determined following 4, 24, 48, 72 and 96 h after administration in carcinoma bearing Balb-C mice. The Table 3 represents the biodistribution of our formulation as ID/g% in blood and other organs, including tumor site. ID/g% represents the percentage of radioactivity of each organ per gram of that organ. Figure 4 displayed comparison of ID/g% in blood, liver, kidney, tumor and other organs. Table 3Biodistribution of 111In-albumin-loaded liposomal formulation in mice at 4, 24, 48, 72 and 96 h after administration, represented as Injection Dose/gram (ID/g). n = 3 at each time pointOrgansID/g % for each organ, at times (h) after administration4 h24 h48 h72 h96 hBlood11.97 ± 3.073.89 ± 0.481.73 ± 0.321.03 ± 0.170.46 ± 0.02Heart4.56 ± 1.852.68 ± 0.303.47 ± 0.843.74 ± 0.903.21 ± 0.18Lungs9.28 ± 2.848.65 ± 2.287.69 ± 3.234.91 ± 0.936.71 ± 1.87Liver7.92 ± 2.0312.39 ± 2.2814.63 ± 1.1128.36 ± 3.3224.52 ± 2.42Spleen6.31 ± 2.7720.67 ± 2.0617.97 ± 2.5719.25 ± 3.8413.62 ± 1.37Stomach5.06 ± 4.381.38 ± 0.481.02 ± 0.512.43 ± 0.731.44 ± 0.64Intestine8.26 ± 6.086.31 ± 0.704.58 ± 0.824.67 ± 0.952.22 ± 0.57Kidney10.86 ± 3.6734.73 ± 5.5423.43 ± 8.0623.31 ± 2.6917.26 ± 2.77Tumor5.06 ± 1.348.73 ± 1.107.34 ± 0.356.77 ± 0.865.71 ± 1.28Muscle1.54 ± 0.531.65 ± 0.201.69 ± 0.403.08 ± 1.971.75 ± 0.96Bone3.44 ± 1.037.31 ± 1.656.54 ± 1.113.95 ± 0.535.56 ± 2.87Tail7.93 ± 1.542.80 ± 1.663.23 ± 2.433.24 ± 2.281.38 ± 0.40Tumor/Blood ratio0.422.244.246.5712.41Tumor/Muscle ratio3.285.294.342.193.26 Biodistribution of 111In-albumin-loaded liposomal formulation in mice at 4, 24, 48, 72 and 96 h after administration, represented as Injection Dose/gram (ID/g). n = 3 at each time point Comparison of biodistribution of 111In-albumin-loaded liposomal formulation in mice at 4, 24, 48, 72 and 96 h after administration in specified organs, represented as Injection Dose/gram (ID/g). n = 3 at each time point According to the Table 3, after 4 h post injection, the accumulated radioactive dose in all organs were observed and blood had absorbed highest dose at this time point. Accumulated radioactive doses in kidney, Spleen and liver were higher in comparison to other organs at 24 h post injection and remarkably, the accumulated dose within tumor tissue was considerably high. Moreover, the formulation in the blood was persisted significantly in this period of time and therefore has shown considerable stability. After 48 h post injection, blood concentration of formulation was decreased but accumulated dose within kidney, spleen and liver were higher than other organs and furthermore, tumor site had remarkable concertation of formulation in comparison to the blood (p value < 0.05) as well. At 72 h post administration, the accumulated dose in the liver, spleen and kidney is higher than other organs, and unlike the previous times, the liver dose is higher than the spleen dose. However, despite the formulation being cleared from the blood, it is still stable within the tumor site. At last, in 96 h post injection, accumulated dose in the liver, kidney, spleen and tumor is still high even after 96 h. An important finding of our study is the lowest amount of dose reduction calculated in the tumor during 96 h after injection as demonstrated by accumulated radioactivity within the tumor in comparison to the blood. According to Fig. 5 tumor/blood ratio, as an important factors in drug delivery to tumor, has increased significantly over the time period from 4 h to 96 h. Tumor/Blood ratio of 111In-albumin-loaded liposomal formulation in mice at 4, 24, 48, 72 and 96 h after administration Gamma scintigraphy of radiolabeled liposomal formulation administered tumor bearing Balb-c mice Gamma scintigraphy of these mice has demonstrated visual depiction of biodistribution. Figure 6 displays static scintigraphy images of the mice subjected to formulation at times points of 4, 24, 48 and 96 h after administration. Figure 7 represents dynamic scintigraphy image at 4 h. As demonstrated in Fig. 6, tumor site has shown aggregation of radiolabeled liposomes and the resolution of image has enhanced over this time period in all scintigraphy images. Area with high aggregations pertains to the kidneys and the reticuloendothelial system of spleen and liver, that in them entrapment of nanoliposomes is occurred. These organs are still visible as hot spots in imaging from the initial hours to 96 h after injection of the formulation. Remarkably, according to the detected radioactivity, it seems that even at times after 96 h, imaging can be continued and the tumor can be evaluated more clearly. Planar scintigraphy images of mice administrated 111In-albumin-loaded liposomal formulation at A 4, B 24, C 48, and D 96 h post injection. Ant: Anterior view, Post: Posterior view Dynamic scintigraphy image at 4 h. Ant: Anterior view, Post: Posterior view Discussion Various approaches have been explored to make efficient imaging of tumors and inflammatory conditions (Del Vecchio et al. 2007; Gomes Marin et al. 2020; Weber et al. 2020; Bai et al. 2023). Liposomes as pharmaceutical nanocarrier have been exploited in the field of drug delivery, and also tumor imaging (Man et al. 2019). Characteristics of liposomes including their size and PEGylation influence their stability in vivo and their removal by phagocytes after administration (Filipczak et al. 2020). Radiolabeled liposomes can be particularly useful in imaging of location of infection and tumors in the body (Boerman et al. 1995; Tzror-Azankot et al. 2024). 111In is a radionuclide emitting two gamma photons with energy of 173kev and 247kev and used in clinical imaging. In comparison to 99mTC (half-life 6 h), the half-life of 111In is longer and is about 67.2 h. Furthermore 111In has higher accumulation activity than 99mTc (Awasthi et al. 1997; Munekane et al. 2022). The binding of 111In with proteins such as albumin is 1012 folds stronger than its binding with oxine (Dillehay et al. 2006). 111In-oxine, which is a lipophilic compound, enters the liposome and interacts with encapsulated albumin within the liposome and because of high affinity of 111In with albumin, 111In-albumin conjugation is formed and oxine is released and leaves the liposome (Dillehay et al. 2006; Owen et al. 2020). Concisely, we analogize the liposome as to the cell, and the albumin as to the intracellular proteins. Using this approach for the first time, we radiolabeled albumin-loaded liposomes with 111In-oxine. In this work, we formulated PEGylated liposomes containing 111In-albumin and investigated the characteristics of these liposomes, in vitro release of them in serum medium, biodistribution of 111In-albumin containing liposomes in tumor-bearing mice, and their scintigraphy images. Mean size of liposomes was 130 nm, which is a proper particle size to be concealed from the reticuloendothelial system, and consequently more entrapment in tumor area by EPR effect. EPR mechanism is a critical contributor of drug-loaded nanocarriers for permeation into tumors (Torchilin 2011; Subhan et al. 2023). PEGylation of liposomes is another factor for enhancement of EPR phenomenon (Harris and Chess 2003; Shen and Yuan 2023; Khajeei et al. 2024). Our liposomes have zeta potential of about − 13.5 mv because of the presence of PEG that gives negative charge to the surface of liposomes. PDI of these nanoliposomes was less 0.2, indicating homogeneity of the size of the liposomal formulation. AFM and TEM microscopy showed almost spherical structures which also in the respect to their size were in good correlation with dynamic light scattering results. Encapsulation percentage of albumin in liposomes was approximately 45% which is similar to studies conducted on protein-encapsulating liposomes that their percentages in those studies approximately range from 30 to 47% (Nikpoor et al. 2015; Yazdi et al. 2020; Jash et al. 2021). The stability of these liposomes was first evaluated in the serum medium as in vitro study. Our results indicated that high stability of our formulation, due to its low release rate up to 24 h. Similar to Doxil formulation, our albumin-containing liposomes have a very low release rate (maximum 10%) in the serum medium, and consequently is expected higher entrapment into the tumor area and thereafter, the phospholipases of the interstitial fluid cause degradation of the lipid bilayer of liposomes (Patel 1996; Barenholz 2012). We conducted biodistribution study in mice bearing C-26 colon carcinoma. First obvious result is accumulation of liposomal formulation in reticuloendothelial system, such as the liver and spleen that is expected from their tissue structure. The important finding of our biodistribution study is increased accumulation of our formulation in tumor area through EPR phenomenon, in part because of the presence of the PEG molecule on these liposomes. Liposomes containing PEG have more stability in blood circulation compared to liposomes without PEG (Harris and Chess 2003). PEG molecules usually enter the liposomal bilayer and form a hydrated shell on the surface of liposomes, which protects the liposomes from being destroyed by plasma proteins. Increased stability of PEGylated liposomes derives from the PEG molecules that resulting in decreased uptake of these liposomes by the reticuloendothelial system, which, therefore, reduces their clearance from the blood, and enhances their half-life in the blood circulation. Furthermore, negative surface charge of PEGylated liposomes is lower compared to non-PEGylated liposomal formulations, which this charge induced by PEG reduces their absorption by reticuloendothelial system (Lee et al. 2005; Jain and Stylianopoulos 2010; Raina et al. 2021). In a study by Lee and his colleagues (Lee et al. 2005) using rats to investigate the biodistribution of radiolabeled liposomes, they concluded that liposomes not containing PEG are cleared from the blood within 4 h after injection and enter the liver and spleen. However, with adding of 5% PEG in the lipid composition of liposomal formulation, the accumulation of liposomes in the liver decreased and highest stability of liposomes in the blood was pertained to the liposomal formulation with 9.6% PEG concentration. Furthermore, another their conclusion was accumulation of liposomes in the liver is directly related to their size, so increasing in size increases their accumulation in the liver. The accumulation in the spleen, in addition to the size of the liposomes, depends on the PEG percentage of the formulation as well. The study of Awasthi and his colleagues (Awasthi et al. 2003) further confirmed the finding that accumulation of liposomal formulation in the liver, spleen and blood is more than other organs after in vivo administration. The high accumulation in the RES system, such as the liver and spleen, is due to their special vascular structure having pores and fenestrations, therefore liposomal particles are collected in this area. In addition, macrophages of liver and spleen break down liposomes, and their released 111In is excreted by the kidneys. In our study, the highest accumulation was in the liver at 72 h and in the spleen at 24 h. The higher absorption of the spleen compared to the liver in 24 to 48 h, and the increased absorption of the liver compared to the spleen in 72 to 96 h are also significant. This is because of absorption of the particles larger than 160 nm in the spleen and absorption of smaller particles in the range of 30–160 nm in the liver. In the earlier hours of filtration, larger particles are filtered by the spleen, and after 48 h, the smaller particles are removed by the liver. The increased accumulation of formulation in the kidneys is associated with the degradation of liposomes and the clearance of released 111In by the kidneys. One of our unexpected results was the high absorption in the kidneys, despite of the proper stability of liposomes in the first 24 h after administration. This phenomenon could be associated with the low QC of purchased 111In-oxine radiopharmaceutical, leading to poor liposomal radiolabeling of about 20%. The existence of 80% free 111In (80%) in the formulation caused non-specifically binding to the outer surface of liposomes and after injection, free 111In, not bonded to the albumin, separates from the liposomes over time and high excretion of this non-specific free 111In from the kidneys was taken place. Lung, bone, stomach, muscle and intestine have similar vascular tissue, and the absorption of our radiolabeled liposomes is similar with a reflection to the blood level. The most important finding of our biodistribution study in comparison to other studies investigating biodistritribution of free radiolabeled-antibody and liposomal-111In not including albumin, was the relatively high and significant accumulation of our albumin-111In loaded liposomal formulation in tumor site after 24 h of intravenous injection which was prolonged in the tumor up to 96 h, therefore made it possible to evaluate the tumor up to 96 h and probably so on after administration. The increase in Tumor/blood ratio between 4 and 96 h was considerably significant and confirms that our formulation has greatly improved the absorption rate of the tumor compared to the blood level. Absorption of radiopharmaceuticals in tumors as well as abscesses and foci of infection and inflammation is due to the EPR phenomenon. Numerous studies have shown that liposomes are probably entrapped in these areas due to increased capillary penetration or damage of the layers of vascular endothelial cells (Sun et al. 2022; Kim et al. 2023). As mentioned earlier, PEGylated liposomes well demonstrate this phenomenon. One of the biggest challenges facing the use of the free form of proteins in the diagnosis and scintigraphy of tumors is their lack of sufficient accumulation in the tumor area following intravenous administration and non-specific accumulation in non-target organs. On the other hand, the EPR mechanism is a main mechanism for the entry of nanocarrier such as liposomes smaller than 200 nm into the tumor area. As a result, based on our biodistribution results, 111In-albumin encapsulated in PEGylated liposomes is an efficient approach for radio imaging because of its high stability in bloodstream and more accumulation within tumor site. In addition, the high half-life of 111In and its high binding strength with albumin and stability of this formulation confirmed by imaging up to 96 h, have led to the possibility of imaging the tumor in a longer period of time for clinical application. In the other study, Boerman and his colleagues (Boerman et al. 1995) investigated the biodistribution of PEGylated liposomes labeled with 111In compared to 111In bound to IgG antibody in rats with focal staphylococcus aureus infections. In that study, they found that the removal of radioactive labeled material in the abscess with liposomes containing 111In was 2 times of the removal of 111In-bound IgG. Considering the biodistribution of our 111In-albumin liposomal formulation and the biodistribution of In-IgG and In-liposome in Boerman’s study reveals that formulation stability in the blood and Tumor/blood ratio as well as tumor accumulation have been significantly improved. Especially, with our formulation, it is possible to examine the tumor for up to 96 h and even more over. In this research, scintigraphy imaging in mice was also performed, and the information obtained from the scintigraphy was consistent with the results obtained from biodistribution study. In the time period of experiment, the contrast between the tumor and the background was enhanced and the higher uptake in the tumor as well as in the liver, spleen and kidneys forms a distinct localization in scintigraphy images. Conclusions Carefully designed radiopharmaceutical agents play a central role in nuclear medicine. In this study for the first time, radiolabeled 111In-albumin encapsulated liposomes were prepared by using high binding affinity of 111In to the albumin molecules entrapped into the liposome. Our biodistribution study and scintigraphy images demonstrated that 111In-albumin encapsulated liposomes have high stability and efficiency that could be exploited in long-term tumor imaging. Further studies including randomized clinical trial is needed for its clinical application. Acknowledgements The support of the Nanotechnology Research Center, Mashhad University of Medical Sciences and Department of nuclear medicine, Ghaem Hospital, Mashhad University of Medical Sciences is gratefully acknowledged. We would like to thank Dr Amin Reza Nikpoor for his excellent assistance. Author contributions M.A: Investigation, Formal analysis, Writing—original draft. Z.A, A.A and J. RY: Investigation, Visualization, Software, Writing—original draft. MR. J: Project administration, Formal analysis, Conceptualization, Writing—review and editing, Resources. K.S: Project administration, Formal analysis, Conceptualization, Writing—review and editing, Resources. All authors read and approved this final manuscript. Funding This study was a part of Mohammad Ahrari M.Sc. dissertation with master thesis code 11130512942015. This study was supported by Vice Chancellor for Research and Technology, Mashhad University of Medical Sciences. Data availability The data produced during this research study are available from the corresponding authors upon request. Declarations Conflict of interest The authors declare no competing interests. Ethical approval and consent to participate All animal experiments were conducted in accordance with the approval of Institutional Ethical Committee of Mashhad University of Medical Sciences in accordance with the principles of the Declaration of Helsinki. Consent to participate was not applicable as this study did not involve human subjects. (Master thesis code: 11130512942015). Consent to publish Not applicable as this study did not include human subjects. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The data produced during this research study are available from the corresponding authors upon request.